GlassScriptPhysician profile
Kevin E Sanders
NPI 1376554154
$4,140.86
in general payments reported to CMS, 2019-2025
34 companies · $541 in 2025
The $541 reported for 2025 was more than what 76% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $43.60 · 2021: $433 · 2022: $869 · 2023: $918 · 2024: $947 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,406.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reflexion Medical, INC. | $873.09 | 2021-2023 | Reflexion Medical Radiotherapy System |
| Elekta, INC. | $792.04 | 2019-2024 | Elekta Medical Linear Accelerator |
| Telix Pharmaceuticals | $633.89 | 2023-2025 | Illuccix |
| Boston Scientific Corporation | $290.91 | 2019-2021 | |
| Palette Life Sciences, INC. | $257.07 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $153.97 | 2020-2024 | Imfinzi, Enhertu, Lynparza |
| Visionrt, INC. | $150.39 | 2023 | |
| Bioprotect Medical, INC. | $107.74 | 2024 | Bioprotect Balloon Implant System |
| Merck Sharp & Dohme LLC | $91.33 | 2023-2025 | Keytruda, Reblozyl, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $72.29 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $69.24 | 2022-2024 | |
| Intuitive Surgical, INC. | $57.69 | 2022 | |
| Profound Medical Corp. | $50.52 | 2021 | |
| Siemens Medical Solutions USA, INC. | $47.53 | 2024-2025 | Varian Ethos Treatment Planning |
| Daiichi Sankyo INC. | $44.25 | 2022-2024 | Vanflyta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $43.51 | 2022 | |
| Pfizer INC. | $43.02 | 2024-2025 | |
| Incyte Corporation | $42.97 | 2023-2025 | Jakafi, Niktimvo |
| Rigel Pharmaceuticals, INC. | $39.07 | 2019-2020 | |
| Progenics Pharmaceuticals, INC. | $27.01 | 2023 | Pylarify |
| Regeneron Healthcare Solutions, INC. | $24.27 | 2024 | Libtayo |
| Genmab U.S., INC. | $21.57 | 2024 | Epkinly |
| Ge Healthcare | $20.21 | 2021 | |
| Blue Earth Diagnostics | $19.93 | 2024 | |
| Tersera Therapeutics LLC | $18.70 | 2023 | Zoladex |
| Janssen Biotech, INC. | $18.35 | 2023 | Darzalex, Tecvayli |
| Coherus Oncology, INC. | $18.28 | 2024 | |
| Lilly USA, LLC | $17.38 | 2019 | |
| Eisai INC. | $16.93 | 2023 | |
| Abbvie INC. | $16.76 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $15.96 | 2023 | Imbruvica |
| Sumitomo Pharma America, INC. | $15.90 | 2023 | Orgovyx |
| Geron Corporation | $15.00 | 2025 | Rytelo |
| Myriad Genetic Laboratories, INC. | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.